Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy

Update Il y a 4 ans
Reference: NCT00347698

Woman and Man

  • | Country :
  • Mexico
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of the study is to evaluate the safety and efficacy of 2.5 mg of intravitreal bevacizumab in one eye, versus panretinal photocoagulation in the contralateral eye, for the treatment of patients with untreated symmetric proliferative diabetic retinopathy.


Inclusion criteria

  • Diabetic retinopathy

Links